top of page

News

Portfolio Press Release

January 13, 2021

Landos Biopharma guns for a $100M IPO to boost AI autoimmune R&D work

December 08, 2020

Pipeline Therapeutics to Participate in the 2020 RBC Capital Markets and SVB Leerink Private Company Conferences

Oct. 14, 2020

Totient Leverages Integral Molecular's Membrane Proteome Array to Advance Cancer Therapeutic Discovery

Sept. 18, 2020

Pipeline Therapeutics Appoints Lori Lyons-Williams to its Board of Directors

Sept. 10, 2020

Totient Partners with Ginkgo Bioworks to Apply Unique Discovery Platform to COVID-19 Antibody Efforts

Sept. 10, 2020

Totient Comes Out of Stealth with Novel COVID-19 Program and $10M in Seed Funding for AI-Driven Drug Discovery Platform

July 28, 2020

Pipeline Therapeutics to Present at 3 Upcoming Investor Conferences

July 23, 2020

Pipeline Therapeutics Initiates Phase 1/2a Clinical Trial of PIPE-505 in Sensorineural Hearing Loss

July 17, 2020

X-Vax Technology Appoints Issac Blech as Vice Chairman to its Board of Directors

July 14, 2020

Landos Biopharma Announces First Human Dosing in a Phase 1 Study of NX-13, its novel candidate for Inflammatory Bowel Disease

Dec 2019

Pipeline Therapeutics Completes $30 Million Series B Financing

Nov 2019

Landos to Present at the 31st Annual Piper Jaffray Healthcare Conference

Sept 2019

Tangible Science, VSP Optics introduce Unity BioSync Contact Lenses

Aug 2019

Landos launches two phase II trials

Aug 2019

Landos Biopharma Completes $60 Million Series B

Jul 2019

X-Vax Technology Raises $56 Million in Upsized Series A

May 2019

Landos Biopharma Announces Publication of Results from First-in-Human Phase 1 Study of BT-11 in Healthy Volunteers

Jan 2019

New Data Demonstrates That Scleral Lenses Coated With Tangible® Hydra-Peg® Improve Dry Eye Symptoms, Comfort, Lens-Related Ocular Surface Changes and Fogging

Dec 2018

FDA Clears First Daily Disposable Silicone Hydrogel Contact Lense Coated with Modified Formula of Tangible® Hydra-PEG

bottom of page